Medtronic and UnitedHealthcare Release Successful Value-Based Healthcare Data
Posted on July 10, 2018 by Medtech[y] Staff
Medtronic's value-based healthcare initiative has been a consistent conversation on our forums with community members trying to understand the specifics of the program and its benefit to the healthcare system as a whole.
Some of the confusion was cleared up today as Medtronic and UnitedHealthcare announced first year results from their value-based relationship, which is focused on delivering patient-centered solutions that improve health outcomes while reducing soaring healthcare costs related to managing diabetes.
The two companies expanded their relationship in 2016, giving UnitedHealthcare members with diabetes access to advanced insulin pump technologies and comprehensive support services offered by Medtronic.
Results from an analysis of over 6,000 members with diabetes on Medtronic MiniMed(TM) 630G and previous generation insulin pumps demonstrated 27 percent fewer preventable hospital admissions compared to plan participants who are on multiple daily injections of insulin (MDI). The analysis included a mix of members utilizing both standalone insulin pumps and pumps integrated with continuous glucose monitors (CGM).
"These positive results provide further evidence of the benefits of both automated insulin delivery and of value-based healthcare models" said Hooman Hakami, executive vice president and president of the Diabetes Group at Medtronic. "Through this unique partnership, Medtronic and UnitedHealthcare have demonstrated a commitment by both organizations to prioritize innovation that improves health outcomes and lowers healthcare costs. At Medtronic, our commitment is to drive innovation with the clear objective of delivering demonstrable value to patients and to the healthcare system. Our hope is that this agreement is just the beginning and that the entire healthcare community follows UnitedHealthcare's lead to not only champion innovation in diabetes that has a clear and measurable tie to better outcomes and lower cost, but to also drive business models that reward those results as they are achieved."
What is Medtronic's Value Based Healthcare?
This data reflects first year results of a multiyear initiative between UnitedHealthcare and Medtronic. Both quality of care and cost will continue to be closely evaluated over the duration of the relationship, providing additional opportunities for more people enrolled in UnitedHealthcare plans to better manage their diabetes and for quality care to be delivered in a more cost-effective manner.
"These results show that patients with diabetes can benefit from using insulin pumps and comprehensive support services, thereby increasing the quality of the care they receive and reducing hospital admissions as well as costs," said Peter Pronovost, M.D., chief medical officer, UnitedHealthcare. "The first-year results are encouraging, and we will monitor patients using Medtronic pump therapies to ensure we continue to see improved quality of care, fewer hospitalizations, and lower costs."
Care providers nationwide are showing strong interest in a shift to value-based care. UnitedHealthcare's total payments to physicians and hospitals that are tied to value-based arrangements have grown in the last three years to $65 billion. By the end of 2020, UnitedHealthcare expects that figure to reach $75 billion.